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ABSTRACT 
Tenofovir renal toxicity, particularly when associ-
ated with other antiretrovirals, has been reported in 
the adult HIV-positive population. Reports in HIV-
positive children are very rare. The authors report a 
paediatric case of nephrotoxicity associated with 
tenofovir and didanosine, emtricitabine and lopinavir-
ritonavir coadministration.
A 12-year-old girl with AIDS (clinical stage C) with 
a multidrug-resistant virus and several treatment 
failures initiated emtricitabine, tenofovir, didanosine 
and lopinavir-ritonavir in 2008 with good tolerance. 
Her viral load became undetectable and CD4 count 
normal. Two years later she presented generalised 
weakness, polydipsia and polyuria. On physical 
examination dehydration was evident. Her vital signs 
were stable. She had lost 5% of her body weight 
in the previous week. Urinalysis revealed a urine 
gravity of 1000, osmolality 150 mOsm/Kg and no 
proteinuria or glucosuria. Blood analysis showed 
osmolality 289 mOsm/Kg, normal values of glucose, 
creatinine, urea, sodium, potassium, chloride and 
calcium. A water restriction test followed by des-
mopressin administration confirmed the diagnosis 
of nephrogenic diabetes insipidus. Tenofovir and 
didanosine were stopped and abacavir was added. 
The patient was treated with a thiazide diuretic and 
salt restriction. There was good clinical evolution 
and no relapses.
This case highlights important possible side effects 
of tenofovir and emphasises the need for further 
studies into the renal safety of this agent in paediatric 
patients.
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INTRODUCTION 
Tenofovir is a nucleotide reverse transcriptase 
inhibitor. While preclinical studies considered it to 
be effective and more secure than other members 
of this pharmacological class1, recent years have 
seen reports of nephrotoxicity in the adult HIV-
positive population2,3 but very few in children4,5. In 
fact, there is little knowledge of its effects in the 
paediatric population. Two randomised studies sug-
gested a safe profile6,7 but, more recently, a multi-
centre cohort study with forty patients showed sig-
nificant association between tenofovir and renal tubular 
dysfunction in HIV-infected paediatric patients8.
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The nephrotoxicity occurs as a result of tubular 
damage that can cause Fanconi Syndrome, renal 
failure and nephrogenic diabetes insipidus (NDI)1-8. 
We present the case of a female adolescent with 
AIDS who developed NDI while on rescue antiretro-
viral (ARV) regimen with lopinavir-ritonavir, didanos-
ine and emtricitabine-tenofovir.
CASE REPORT 
We report the case of a 12-year-old Caucasian 
female born from a pregnancy with no clinical sur-
veillance. At the age of eight months she was admit-
ted to our hospital with Pneumocystis jiroveci pneu-
monia and HIV1 infection was diagnosed (CDC 
category C3).
At fifteen months of age she had a disseminated 
BCG infection and systemic candidiasis, and at the age 
of eight had pulmonary tuberculosis. She also had HIV 
encephalopathy, spastic diplegia and epilepsy.
ARV treatment compliance was difficult, and the 
patient had a multidrug-resistant virus and several 
treatment failures. In May 2010 she began complain-
ing of generalised weakness, polydipsia and polyuria 
(>5 ml/kg/h). The patient was since 2008 on rescue 
ARV regimen with lopinavir-ritonavir 200 + 50 mg 
twice daily; didanosine 125 mg twice daily and emtric-
itabine-tenofovir 200 + 300 mg once daily, with unde-
tectable viral load and normal CD4 cell count.
On physical examination she had sunken eyes 
and dry mucous membranes. Her vital signs were 
stable (blood pressure 109/68 mm Hg; heart rate 90 
beats per minute; temperature 37.1ºC; respiratory 
rate 14 cycles per minute). She had lost 5% of her 
body weight in the past week.
Urinalysis revealed a urine specific gravity of 1000, 
osmolality 150 mOsm/Kg, phosphaturia: reabsortion 
rate of phosphorus was 84.4% (N: 92.5±2.3 %) and 
no proteinuria or glucosuria. Blood analysis showed 
osmolality 289 mOsm/Kg, normal values of glucose 
(116 mg/dl), creatinine (0.56 mg/dl), urea (12 mg/dl), 
sodium (140 mmol/l), potassium (4.52 mmol/l) and 
calcium (2.22 mmol/l). She had hypophosphataemia 
(0.56 mmol/l) with PTH slightly decreased (9.9 pg/
ml, N: 15-65).
The patient was admitted for a water restriction 
test followed by desmopressin administration (20μg 
intranasal) that confirmed the diagnosis of NDI:
– ADH levels before the test were slightly raised: 
14.4 pmol/L (N: 2-13)
– There was elevation of blood osmolality (297 
mOsm/Kg) without elevation of urine osmolality 
(194 mOsm/Kg), reflecting the inability to con-
centrate urine;
– Desmopressin administration caused no significant 
elevation of urine osmolality (219 mOsm/Kg).
Tenofovir and didanosine were stopped and aba-
cavir was added. She also started a thiazide diuretic 
and salt restriction diet. There was good clinical 
evolution with progressive weight gain and symptoms 
resolution within a month. Her blood and urinary 
values of phosphorus also became normal and there 
were no relapses, with viral load remaining undetect-
able and normal CD4 count.
DISCUSSION 
Toxicity can limit the use of successful antiretro-
viral regimens. Tenofovir has nephtotoxic potential, 
which has been related to dose and duration of 
therapy5,8. It should be used with great caution and 
the coadministration of didanosine avoided whenever 
possible. However, treatment options are frequently 
very scarce in antiretroviral experienced children with 
multidrug-resistant virus. They present complex thera-
peutical challenges that need a careful clinical and 
laboratory follow-up5,8.
This case highlights important possible side 
effects of this agent and emphasises the need for 
further studies into the renal safety of tenofovir in 
paediatric patients. Renal complications of this drug 
should be anticipated by appropriate screening8 and 
treatment discontinued if they are confirmed. 
Research is under way into new, structurally similar 
molecular derivatives which do not accumulate in 
proximal tubules9.
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